Cerus (CERS)

• Market cap: $258M
• 1 day: -6.08%
• 5 days: -7.95%
• 1 month: -22.78%
• 3 months: -18.71%
• 6 months: -32.85%
• Year to date: -11.46%
• 1 year: -31.53%
• 5 years: -66.18%
• 10 years: -66.26%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Employees: 281

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

3,362% more call options, than puts

Call options by funds: $450K | Put options by funds: $13K

94% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 32

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

3% more funds holding

Funds holding: 147 [Q3] → 151 (+4) [Q4]

1.01% less ownership

Funds ownership: 80.5% [Q3] → 79.49% (-1.01%) [Q4]

12% less capital invested

Capital invested by funds: $260M [Q3] → $227M (-$32.2M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 188% upside
• Avg. target: $4 188% upside
• High target: $4 188% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Ross Osborn 46% 1-year accuracy 21 / 46 met price target

188% upside $4

Overweight Reiterated

21 Feb 2025